EXPRESSION PLASMIDS USEFUL IN B. SUBTILIS

Abstract: A new vector system is described for expression of prochymosin in B. subtilis. The vector system includes the prochymosin encoding gene and an erythromycin resistant promotor and can be integrated into a B. subtilis host organism as an expression plasmid adapted for transforma­ tion.

Description: This invention relates to expression vectors useful in Bacillus subtilis . More particularly it relates to expression plasmids capable of expressing heterogeneous gene in B . subtilis under control of a E m r promoter, and to methods for expression of prochymosin cDNA in B . subtilis by means of said expression plasmids carrying the E m r promoter. B . subtilis has been extensively studied from genetic and biochemical points of view, and is neither parasitic nor pathogenic to human or animal. Further, B . subtilis has a strong propensity to extracellularly secrete proteins produced. By this propensity it has become possible that Recombinant DNA technology is applied to have heterogeneous gene-derived products secreted extracellularly. Thus B . subtilis is considered as safe and valuable host organism when the Recombinant DNA Technology is tried on microorganism. However, as compared to E . coli , there are fewer successful instances wherein heterogeneous gene can indeed be expressed in B . subtilis as host organism: the major causes are the instability of plasmids within B . subtilis cells and the presence of strong proteolytic enzymes inherent in B . subtilis . It is an objective of this invention to effect the heterogeneous gene expression in B . subtilis , and therefore to develop a new host-vector system for that purpose. It is another objective of this invention to construct expression vectors capable of expressing genes in B . subtilis when the organism contain a promoter comprising an erythromycin-resistant (E m r) gene. It is a further objective of this invention to achieve the expression of prochymosin gene in B . subtilis by using the above-stated expression vectors. The above described objectives and many other objectives as well as advantages associated with this invention will become clearer by reading the following description. Prochymosin is secreted by the calf fourth stomach (abomasum), and is a precursor protein of chymosin which is responsible for coagulating milk in the manufacture of cheese. Prochymosin has a molecular weight of about 40,000 and consists of 365 amino acid residues. A peptide consisting of 42 amino acids is cleaved from the N-terminus of prochymosin by self-digestion, resulting in the formation of chymosin. Recently milk-coagulating enzymes, of microbial origin, have been discovered and these are substituting for chymosin. Nevertheless, the need still exists for calf prochymosin in the cheese industry. Accordingly, it is one of the primary objectives in the application of Genetic Engineering to utilize the recombinant DNA technology and to have microorganisms produce the calf prochymosin. Several successful instances have been reported wherein the recombinant DNA technology is applied to the production of prochymosin by E . coli host organism. For example, relevant references are: Nishimori et al ., Gene, 19 , 337 (1982); Japan Kokai 58-32,896 (to Teruhiko Beppu); Japan Kokai 57-141,287 (to Collaborative Research Inc.); and Japan Kokai 58-9,687 (to Celltech Ltd.). Additionally, B . subtilis is disclosed as a host organism for production of the principle antigen for aphthous fever as well as for production of β-interferon, respectively in K, Hardy et al ., Nature, 293 , 481 (1981) and S. Chang et al ., "Molecular Cloning and Gene Regulation in Bacilli", Academic Press, 159 (1982). According to this invention there is provided a process for the production of prochymosin comprising the following steps: a) inserting a prochymosin gene into a B . Subtilis vector system containing a promoter, with the proper reading frame, to form an expression plasmid; b) transforming a B . subtilis host organism with the expression plasmid to obtain transformants; c) selecting drug resistant transformant among the thus-obtained transformants; d) growing said drug resistant transformant in a nutrient medium, and; e) isolating prochymosin from the culture obtained in step (d). In another aspect of this invention there are provided expression plasmids including an E m r promoter and a prochymosin cDNA sequence and capable of expressing prochymosin in host organism under control of the promoter. Also included in this invention are methods for the construction of the novel expression plasmids, microorganisms transformed with said plasmids, and the prochymosin produced by the above-stated process. In order to describe the invention fully, the description of preferred embodiments will follow. In the attached Drawings, figure 1 shows restriction enzyme map of 29K Protein. Figure 2 shows a scheme for the construction of plasmid pKS3 from plasmids pHW1 and pMC1396, including the base sequence of pMC1396 around its Small site and of pHWI around its HaeIII site. Figure 3 shows a scheme for the construction of plasmid pCR702 from plasmids pCR701 and pBR322. Figure 4 shows a scheme for the construction of plasmid pKSR101 from plasmids pCR702 and pKS3. The Host Microorganisms Wild-type species of B . subtilis demonstrate a defence mechanism against invading heterogeneous genes when introduced to their intracellular structure. Restriction enzymes capable of only cleaving the heterogeneous genes are responsible for that role. Thus, mutant strains deficient in such a restriction system are suitable as host organism. Preferably, a Marbarg 168 derived strain of B . subtilis which is modified to be defective in the restriction system, B . subtilis RM125 ( arg , leu , r⁻, m⁻), is used in this invention. See Uozumi et al ., Molec. gen. Genet., 152 , 65 (1977). The Vectors Suitable and useful vectors that are now commonly used to transform B . subtilis are three kinds of drug resistant plasmids derived from Staphylococcus ; pUB110 (k m r, 3.9Md), pE194 (E m r, 2.4Md), and pC194 (C m r, 2.0Md), respectively. In particular, the pE194 plasmid is valuable in the DNA manipulation, while considering the reading frame, since the entire base sequence of said plasmid is already known. In this invention the use of pHWI (C m r, E m r, 4.3Kb), which is one kind of pE194, is preferred. This particular plasmid is reported in S. Horinouchi, J. Bacteriol., 150 , 8041 (1982). The base sequence of the E m r promoter region within pHWI is, as indicated earlier, known and the promoter shows induction at a low concentration of E m (erythromycin). The E m r gene in the plasmid codes for 23s RNA-methylation enzyme having a molecular weight of 29,000, which enzyme is synthesized inductively under control of the E m r promoter and will be hereinafter referred to as "29K Protein". The Starting Plasmids Plasmid pMC1396 (A p r, lac'2Y, 9.9Kb) is described in M. J. Casadaban et al ., J. Bacteriol., 143 , 971 (1980), and plasmid pHWI (C m r, E m r, 4.3Kb) by Horinouchi (see above). Plasmid pCR701 (A p r, prochymosin, 5.34Kb) is described in N. Shimizu et al ., Abstracts of the Annual Meeting of the Japanese Agricultural Chemistry Society, p.10 (1983), and has been integrated into a strain of E . coli , E . coli c600 r k ⁻ m k ⁻ (pCR701), which is available as FERM BP264 deposited under the terms of the Budapest Treaty in the Fermentation Research Institute, Ibaragi, Japan. Insertion of Heterogeneous Gene into the Restriction Enzyme Sites in 29K Protein E m r Gene Plasmid pHWI contains three restriction enzyme sites within the 29K Protein gene (732bp); the HaeIII site 1256 bp downstream from the ATG start codon; the Bcl site 2216 bp downstream therefrom; and the HpaI site 597 bp downstream therefrom, respectively. Insertion of heterogeneous gene at any of these sites is possible. See Figure 1. Plasmid pKS3 Expression plasmid pKS3 is constructed by integration at the HaeIII site in pHWI of an ampicillin-resistant gene portion (3.7Kb) that is flanked by the BamHI site and by the SalI site in pMC1396. First, the pMC 1396 is completely digested with BamHI and SalI. The linearized DNA is then treated with DNA polymerase (Klenow fragment) at its single-stranded portion, resulting in Fragment (a) (3.7Kb) with both blunt ends. The pHWI is partially digested with HaeIII which cleaves only HaeIII within the E m r gene. The thus produced Fragment (b) (3.4Kb) and Fragment (a) are ligated by means of T₄ DNA ligase. The ligation mixture is transformed into E . coli MC 1064 r k ⁻m k ⁻s m r [M. J. Casadaban et al . J. Bacteriol., 143 , 971 (1980)]. Transformants that are ampicillin and chloramphenicol resistant are selected on the basis of resistance to said reagents. The selected transformants were grown and harvested in a large preparation. Digestion with restriction endonucleases confirms that they carry pKS3. Figure 2 depicts the scheme for construction of pKS3 from pMC1396 and pHWI. The base sequence in the vicinity of the HaeIII site in pK53 is shown: The ability of pKS3 to express heterogeneous genes in a B . subtilis host organism under control of the E m r promoter can be tested in the following manner. First, plasmid pKS3 is cleaved with SmaI and SalI, by which a C m r (chloramphenicol resistant) gene is isolated. Then, β-galactosidase structural gene is isolated from pMC 1403 (A p r, lac'2Y, 9.9Kg) [M. J. Casadaban et al ., J. Bacteriol., 143 , 971 (1980)] by digestion with SmaI and SalI. Both digests are ligated by means of T₄ DNA ligase and the thus produced mixture is transformed into the host B . subtilis RM 125. Transformants are grown in L Broth containing chloramphenicol, erythromycin, and Xgal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) available from Sigma Co. Ltd. If blue colonies are detected in the culture, then it will be clear that β-galactosidase is produced by the transformants. The pKS3 can then express β-galactosidase in the B . subtilis host organism Similarly, it is possible to insert into the BclI Site in the 29K Protein gene, the β-galactosidase structural gene from pMC1403. As described for pKS3, the resulting plasmid can be tested as to whether or not it can express β-galactosidase in the B . subtilis host cells. The same applies to the expression plasmid wherein the HpaI site of the 29K Protein gene is utilized as receiving site of the β-galactosidase gene. Its ability to express β-galactosidase can also be tested accordingly. Based on the results of expression capabilities of β-galactosidase, the highest expression site can be chosen and used for construction of expression vectors including desired heterogeneous genes. Not only the pKS3 but also other expression vectors derivable from pHWI that carries the β-galactosidase insert at its BclI or HpaI site do express said inserted gene; however, the expression levels of the latter vectors are much lower than that of pKS3. Plasmid pCR702 The plasmid pCR701 carries the full-length cDNA of prochymosin. This prochymosin cDNA is, therefore, available from pCR701 by digestion with HindIII and SalI. The cut DNA must, however, contain a poly dG (poly dc) sequence. Since this poly dG sequence lowers the transformation efficiency in B . subtilis , it will be necessary to remove said sequence when the prochymosin DNA is integrated into a B . subtilis expression vector. For this reason, the pCR701 is completely digested with HinfI, and then with nuclease Sl to remove the single-stranded portion. A SalI linker (GGTCGACC) is linked to this fragment consisting of 2550 bp and it is further digested with SalI to isolate fragment(c). Plasmid pBR322 is completely digested with SalI, and then treated with Calf Alkaline Phosphatase to isolate fragment(d). Fragment(c) and fragment(d) are ligated by means of T₄DNA ligase. This ligation mixture is transformed into E . coli MC1064r k ⁻m k ⁺s m r . Transformants are selected based on the ampicillin and tetracycline resistance. These transformant colonies are cultured on a small scale, and plasmid DNA are subjected to restriction enzyme analysis, which verify the presence of pCR702 (5.3Kb). The scheme used for constructing pCR702 from pCR701 and pBR322 is illustrated in Figure 3. It will be recognized that pCR702 is devoid of the SalI-Hinf part of pCR701. Transformants carrying pCR702 produces prochymosin. Plasmid pKSR101 The plasmid pKSR101 has the E m r promoter adjacent to the full-length prochymosin cDNA in the proper reading frame. Construction of pKSR101 is carried out in the following manner. First, pKS3 is doubly digested with BamHI and SalI to isolate DNA fragment(e) containing C m r part of 4.3 Kb. This fragment includes the E m r promoter and a part of the 29K Protein gene. Plasmid pCR702 is completely digested with BamHI and EcoRI to isolate DNA fragment(f) consisting of 465 bp. Further, pCR702 is doubly digested with EcoRI and SalI to isolate DNA fragment(g). Fragments(a) and (b) are both prochymosin cDNAs, and together they will make nearly the full-size prochymosin gene. Fragments (e), (f), and (g) are ligated together by means of T₄ ligase. This ligated DNA is transformed into B . subtilis . Among transformants produced, chloramphenicol resistant colonies are picked, and are found to contain pKSR101 as determined by restriction enzyme analysis. The scheme used for constructing pKSR101 from pCR702 and pKS3 is illustrated in Figure 4. The DNA sequence around the fifth prochymosin codon (CCT) has been shown by the Maxam-Gilbert method to be as follows: Expression of Prochymosin in B. subtilis After B . subtilis transformant cells carrying plasmid pKSR101 have preliminarily been grown in LB broth, cultures are cultivated fully in CH medium. During the latter culturing erythromycin is added to induce gene expression. Cells are collected from the fermentation culture and the cell protein extract is subjected to SDS polyacrylamide gel electrophoresis. If the migrated proteins are blotted onto nitrocellulose filters and are analyzed by the enzyme immunoblotting assay, the prochymosin protein can be detected. The production level of protein is estimated to be around 75,000 to 15,000 molecules per cell, and this quantitation is based on by calibrating the authentic prochymosin. The product protein is in fact a fused protein comprising prochymosin and the 29K protein, and the estimated molecular weight of such a polypeptide is about 45,000. This observation implies that expression in B . subtilis RM125 (pKSR101) of the prochymosin protein fused to 29K Protein is under control of the E m r promoter and that the 29K protein is resulted from the 29K Protein gene which is downstream from the start codon and intervenes between the prochymosin gene and the start codon. E . coli strains or B . subtilis strains produced in this invention, which contain novel expression plasmids, have been deposited in the Fermentation Research Institute, the Agency of Industial Science and Technology, Ibaragi, Japan, under the terms of the Budapest Treaty. They are identified by the accession numbers given thereto. This invention will be described in some more detail by way of illustration and example; nevertheless, it should be understood that certain changes and modifications be practiced within the scope of the invention. EXAMPLE Several kinds of buffered solutions that are used throughout the following examples have compositions as tabulated below. Unless otherwise stated, the TEN buffered solution is employed. Buffered Solution for Use in Gel Electrophoresis 40mM Tris-HCl (pH 7.5) 5 mM CH₃COONa 1 mM EDTA The method of Norgard [M.V. Norgard et al ., Gene, 3 , 279 (1978)] is adapted for E . coli transformation, and the method of Spizizen [J. Spizizen et al ., J. Bacteriol., 81 , 741 (1962)] for B . subtilis transformation. E. coli Transformation E . coli cells are grown in LB broth (10 ml) to densities of 1 to 2 x 10³ cells/ml. The cultured cells are harvested and washed with 10 ml of pCPII. Once again, cells are harvested and suspended in 5 ml PCPII and the suspension is allowed to stand for 20 min. They are reharvested and resuspended in 0.5ml PCPII and competent cells (i.e., cells capable of accepting foreign DNA) are obtained. A transforming DNA insert is added to 0.5 ml competent cell suspension and this is allowed to stand at 0°c for 30-60 min. To the culture 1.8 ml of L broth is added and this is shaken at 37°c for 1.5 h. The resulting cultures (0.1 ml) are inocculated on plates containing a drug such as ampicillin, and drug resistant transformants are sellected. B. subtilis Transformation B . subtilis cells are preliminarily grown in L broth. One tenth of the culture (10 ml) is inocculated on MI (2 ml), and incubated under shaking at 37°c for 4 h. Then one tenth of the resulting culture is inocculated on MII and incubated at 37°c for 1.5 h. The thus obtained competent cells are kept frozen [D. Dubnau et al ., J. Virol., 4 , 50 (1969)]. To these frozen competent cells (0.3 ml) is added EGTA to make up a final concentraiton of 1mM EGTA. After the solution is preincubated at 37°c for 5 min, a transforming DNA solution is added and incubated at 37°c for 45 min. One or two volumes of LB broth are added to she incubated mixture and it is kept at 37°c for 60 min to effect expression. This culture (0.1 ml) is then inocculated on plates containing a drug, and drug resistant transformants are selected. EXAMPLE 1 Construction of pKS3 i) Partial Digestion of pHW (C m r, E m r, 3.4Kb) with HaeIII Plasmid pHW1 was partially digested with HaeIII by incubation at 37°c for 2 min in a 40 µl solution containing TE Plasmid solution 20 µl (50 µg/ml), HaeIII (5U, 1 µl), x10 HaeIII buffer (3 µl) and H₂O (6 µl). The digestion was stopped by phenol treatment, and the resulting DNA (b) was precipitated with ethanol. The DNA was dissolved in 6 µl of H₂O and this dissolved solution was used in the ligation step IV). ii) Complete Digestion of pMC1396 (A p r, lac'z-y, 9.9Kb) with BamHI and SalI A mixture of Plasmid pMC1396 TE solution 20 µl (52 µg/ml), BamHI (30U, 3 µl), and X10 BamHI buffer solution 3 µl was incubated at 37°c for 1 h. The DNA was precipitated with ethanol, and the precipitate was dissolved in 24 µl H₂O. To this dissolved solution was added SalI (30U, 3µl) and X10 SalI buffer 3 µl to make up a 30 µl solution and it was incubated at 37°c for 1 h followed by incubation at 65°c for 10 min. The DNA(a) was precipitated with ethanol. iii) Repairing of the Single Stranded End in DNA Fragment (a) The DNA(a) was dissolved in 29 µl H₂O and to this was added 20mM dNTP (each 2.5 µl; total 10 µl), polymerase buffer 5 µl, and Klenow fragment of DNA polymerase I (1.5U, 1 µl) to make up a 45 µl mixture. It was incubated at 30°c for 10 min. The reaction was terminated by phenol treatment. The resulting DNA was precipipated with ethanol and dissolved in 6 µl H₂O. This dissolved solution was used in the next step. iv) Ligation of DNA Fragment (a) with DNA Fragment (b) A mixture (total volume of 16 µl) of each of 6 µl of DNA (a) and DNA (b) solutions, T₄ ligase (1.8U, 2 µl), 3mMATP (4 µl), and X10 ligase buffer (2 µl) was incubated at 11°c overnight. The ligated DNA was precipitated with ethanol. v) Transformation The DNA was introduced by transformation into competent cells of E . coli MC1064 (r k ⁻m k ⁺sm r ) that were prepared according to the conventional procedure. Among transformants produced, ampicillin and chloramphenicol resistant colonies were selected. Plasmid DNA was extracted from the drug resistant colonies. Restriction endonuclease analysis of the plasmid showed that these colonies contain plasmid pKS3. The strain, designated as E . coli MC 1064 r k ⁻m k ⁺sm r (pKS3), was deposited under the terms of the Budapest Treaty in the FRI with Accession NO. FERM BP-503. EXAMPLE 2 Construction of pCR702 i) Digestion of pCR701 with HinfI Plasmid pCR701 was completely digested with HinfI by incubation at 37°c for 1.5 h in a 100 µl mixture containing Plasmid 65 µl (150 µg/ml), HinfI (35U, 7 µl), x10 Hinf buffer 10 µl, and H₂O 18 µl. The resultant DNA was precipitated with ethanol. The precipitate was dissolved in H₂O (263.7 µl) and this was used in the next step. ii) Nuclease Sl Treatment A mixture (total of 300 µl) of the DNA solution 263.7 µl, Nuclease Sl and X10 Nuclease Sl buffer 30 µl was incubated at 40°c for 30 min. The reaction was terminated by phenol treatment. Phenol was removed by ether extraction. The DNA was precipitated with ethanol. It was then electrophoresed on a 0.8 % agarose gel and the largest DNA fragment (2550 bp) was isolated by electroelution. iii) Ligation of SalI Linker to the DNA Fragment Mixture A was prepared by mixing the DNA fragment (8 µl H₂O), H₂O 4 µl and X5 ligase buffer 1 µl. Next, Mixture B was prepared by mixing SalI linker (GGTCGACC) 3 µl(1 µg/µl), X10 potassium phosphate buffer 3µl, 3mM ATP 3 µl, H₂O 19 µl, and T₄ DNA kinase (6U, 2 µl) and incubating at 37°c for 1 h. After mixure (A) and mixture (B) were mixed, 3mMATP 5 µl and T₄ ligase 3 µl (1.8 µ) were added and the reaction mixture was incubated at 11°c overnight, followed by incubation at 65°c for 10 min. iv) Digestion with SalI To the reaction obtained in step iii) were added SalI (200U, 10 µl), H₂O 117 µl, and X10 SalI buffer 20 µl, and the mixture was incubated at 37 °c for 2 h. Further, to the mixture were added SalI (200U, 20 µl), X10 SalI buffer 20 µl, and H₂O 160 µl and the whole mixture was incubated at 37°c for 2 h, completing digestion with SalI. The resultant DNA was precipitated with ethanol, and electrophoresed on a 0.8 % agarose gel to remove the remaining linker. v) Digestion of pBR322 with SalI and Treatment thereof with Alkaline Phosphatase Plasmid pBR322 was digested with SalI by incubation at 37°c for 1 h in a 70 µl solution containing Plasmid 20 µl (259 µg/ml), SalI (70U, 7 µl), X10 SalI buffer 7 µl, and H₂O 36 µl. The resulting DNA was precipitated with ethanol. The precipitate was dissolved in 78 µl H₂O. To this DNA solution were added X10 DP buffer 9 µl which contains 100 mM MgCl₂ in 0.5M Tris-HCl (pH 8.5) and Calf intestine alkaline phosphatase (6U, 3 µl). The mixture was incubated at 37°c for 1 h. Reaction was terminated by phenol treatment. vi) Religation DNA (c) obtained in step (iv) was dissolved in 40 µl H₂O. Twenty µl was used in ligation. DNA (d) obtained in step (v) was dissolved in 20 µl H₂O. Five µl was used in ligation. Both DNA solutions were mixed. To this were added 3m MATP 7 µl, T₄ ligase (0.9U, 1 µl), and X10 ligase buffer and the mixture was incubated at 21°c for 2h to complete ligation. The ligated DNA was precipitated with ethanol. It was recognized that this ligation process caused deletion of the overlapping part from pBR322 in the resulting DNA plasmid. vii) Transformation The DNA was introduced by transformation into competent cells of E . coli MC1064 (r k ⁻m k ⁺s m r ) that were prepared according to the conventional procedure. Among about 500 colonies, about 70 ampicillin and tetracycline resistant colonies were selected. Plasmid DNA was extracted from the drug resistant colonies. Restriction endonuclease analysis of the plasmid showed that these colonies contain plasmid pCR702. The strain, designated as E . coli MC1064 r k ⁻m k ⁺s m r (pCR702), was deposited under the terms of the Budapest Treaty in the FRI with Accession No. FERM BP-501. EXAMPLE 3 Construction of Plasmid pKSR101 i) Complete Digestion of pKS3 with BamHI and SalI Plasmid pKS3 was completely digested with SalI by incubation at 37°c for 1 h in a 55 µl solution containing Plasmid 30 µl (50 µg/ml), SalI (50U, 5 µl), SalI buffer 5 µl, and H₂O (15 µl). The resultant DNA was precipitated with ethanol. The precipitate was dissolved in 40 µl H₂O. To this dissolved solution were added BamHI (50U, 5 µl) and X10 BamHI buffer 5 µl. The mixed solution was incubated at 37°c for 1 h. The resultant DNA was precipitated with ethanol, and was electrophoresed on an agarose gel and the largest DNA fragment (e) (4.3 Kb) was isolated by electroelution. ii) Double Digestion of pCR702 with BamHI and EcoRI Plasmid pCR702 was digested with EcoRI by incubation at 37°c for 1 h in a 50 µl solution containing Plasmid 20 µl(150 µg/ml), EcoRI (75U, 15 µl), and X10 EcoRI buffer 5 µl, and H₂O 20 µl. To this solution were added BamHI (50U, 5 µl), BamH buffer 5 µl to make up a 50 µl solution. The mixed solution was incubated at 37°c for 1 h. The cut DNA was precipitated with ethanol, and electrophoresed on an agarose gel and the smallest fragment (f) (465bp) was isolated. iii) Double Digestion of pCR702 with EcoRI and SalI Plasmid pCR702 was digested with SalI by incubation at 37°c for 1 h in a 50 µl solution contaiing Plasmid 30 µl (130 µg/ml), SalI (50U, 5 µl), X10 SalI buffer (5 µl), and H₂ (10 µl). The resultant DNA was precipitated with ethanol. The precipitate was dissolved in 40 µl H₂O. To this dissolved solution were added EcoRI (75U, 5 µl) and EcoRI buffer (5 µl) to make up a 50 µl solution. The solution was incubated at 37°c for 1 h. The cut DNA was precipitated with ethanol, and electrophoresed on an agarose gel to isolate the smallest fragment (g) (729 bp). iv) Ligation of DNA Fragments (e), (f) and (g) DNA fragment (e) (4.3 Kb), fragment (f) (4646 bp), fragment (g) (729bp) were dissolved in 18 µl H₂O. To this DNA solution were added T₄ ligase (2.7U, 3 µl) 3mMATP (6 µl), X10 ligase buffer (3 µl) to make up a 30 µl solution. The solution was incubated at 11°c overnight. The ligated DNA was precipitated with ethanol. v) Transformation The DNA was introduced by transformation into competent cells of B . subtilis RM125 ( arg , leu , r⁻, m⁻) that were prepared according to the conventional procedure. Among transformants, two chloramphenicol resistant colonies were selcted, from which plasmid DNA was extracted. Restriction endonuclease analysis of the plasmid showed that these colonies contain plasmid pKSR101. The strain, designated as B . subtilis RM125 ( arg , leu , r⁻, m⁻; pKSR101), was deposited under the terms of the Budapest Treaty in the FRI with Accession No. FERM BP-504. EXAMPLE 4 Expression of Prochymosin in B. subtilis B . subtilis RM 125 carrying pKSR101 was grown in LB broth containing 10 µg/ml of chloramphenicol. Cells were grown in shaker flasks at 37°c overnight. A 0.2 ml culture was inoculated onto CH broth and was incubated at 37°c under shaking. When the cell density reached at about 3 x 10⁷ cells per ml, erythromycin was added (final concentration of 0.05 µg/ml) and cultivation was continued for another hour. One ml of the culture was taken and cells were harvested and washed with cold PBS (20mM phosphate buffer, 150mM NaCl, pH 7.0). Cells were collected again. The cells were then added to 7 µl of lysing buffer (30mM Tris-HCl, 5mM EDTA, 50mM NaCl, 2mM PMSF, pH 8.0) that contains lyzozyme (1 mg/ml). Incubation continued at 37°c for 10 min. Further, 7 µl of x4 Sample buffer (0.0625M Tris-HCl, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, pH 6.8) was added to the above incubated solution, and this was heated at 100°c for 10 min. After addition of 1 to 2 µl of PYRONINE G solution (10 mg/ml ETOH), it was electrophoresed on 10% SDS-polyacrylamide gels. The migrated proteins were blotted onto nitrocellulose filters according to the electroblotting method [B. Bowen et al ., Nucleic Acid Res., 8 , 1 (1980)] using TRANS-BLOT CELL. These nitrocellulose filters were colored and proteins were assayed by BIO-RAD BLOT ASSAY KIT using G oat A nti-Rabbit IgG H orseradish P eroxidase C onjugate): the KIT was purchased from BIORAD Co., Ltd. This analysis (enzyme immunoblotting assay) established that B . subtilis RM 125 (pKSR101) produced the prochymosin-fused protein. In an effort to determine the level of protein expression, the band of the protein produced was compared in intensity with those of varying concentrations of the authentic prochymosin. The intensity of the product protein band was determined to be in the range of from 50 ng to 100 ng of prochymosin. Accordingly, the level of production of the prochymosin-fused protein was about 7,500 - 15,000 molecules per host cell. The estimated molecular weight of the product protein was about 45,000 as measured by using a molecular marker, which value was well in accord with the calculated value assuming that the product protein would be a fused protein of prochymosin and 29K Protein.

Claims: A process for producing prochymosin which process comprises: a) transforming a B . subtilis host organism with the expression plasmid pKSR101 as found in B . subtilis deposited in the FRI as FERM BP-504; b) selecting a chloramphenicol resistant transformant or transformants obtained in step (a); c) cultivating said chloramphenicol resistant transformant or transformants in a nutrient medium; and d) isolating said prochymosin. A process according to claim 1 wherein said B . subtilis host organism is B . subtilis RM 125 (arg, leu, r , m ) as deposited in the FRI as FERM BP-504. A process for producing prochymosin, which process comprises: a) cultivating, in a nutrient medium , a B . subtilis transformant comprising the expression plasmid pKSR101 as found in B . subtilis deposited in the FRI as FERM BP-504; and b) isolating said prochymosin. A process according to claim 3 wherein said B . subtilis transformant is the strain deposited in the FRI as FERM BP-504. An expression plasmid which comprises a E m r promoter and a prochymosin cDNA and is capable of expressing prochymosin in B . subtilis under control of said promoter, said expression plasmid being pKSR101. An expression plasmid according to claim 5 wherein said B . subtilis organism is B . subtilis RM 125 ( arg , leu , r⁻, m⁻). A process for preparing plasmid pKS3 which comprises the steps of a) partially digesting plasmid pHWI with HaeIII to obtain the blunt ended DNA fragment (1); b) digesting plasmid pMC 1396 with BamHI and SalI; c) repairing by means of DNA polymerase the single stranded portion of the DNA obtained in step (b) to form DNA fragment (2); and d) ligating DNA fragments (1) and (2) by T₄ ligase to obtain plasmid pKS3. A process for preparing plasmid pCR702 which comprises the steps of a) digesting plasmid pCR701 as found in E. coli deposited in FRI as FERM BP-264 with HinfI, followed by cutting the single stranded DNA with nuclease Sl to obtain DNA fragment (3); b) attaching SalI linker to DNA fragment (3) and thereafter digesting it with SalI to obtain DNA fragment (4); c) digesting plasmid pBR322 with SalI to obtain DNA fragment (5); and d) ligating DNA fragments (4) and (5) by means of T₄ ligase to obtain plasmid pCR702. A process for preparing plasmid pKSR101 which comprises the steps of a) digesting plasmid pKS3 as found in E. coli deposited in FRI as FERM BP-503 with BamHI and SalI to obtain DNA fragment (6); b) completely digesting plasmid pCR702 as found in E. coli deposited in FRI as FERM BP-501 with BamHI and EcoRI to obtain DNA fragment (7); c) digesting plasmid pCR702 as found in E. coli deposited in FRI as FERM BP-501 with EcoRI and SalI ot obtain DNA fragment (8); and d) ligating DNA fragments (6), (7) and (8) by means of T₄ ligase to obtain plasmid pKSR 101. Plasmid pKS3 found in E . coli deposited in the FRI as FERM BP-503. Plasmid pCR702 found in E . coli deposited in the FRI as FERM BP-501. Plasmid pKSR101 found in B . subtilis deposited in the FRI AS FERM BP-504. E . coli MC 1064 r k ⁻m k ⁺s m r (pKS3) deposited in the FRI as FERM BP-503. E . coli MC1064 r k ⁻m k ⁺s m r (pCR702) deposited in the FRI as FERM BP-501. B . subtilis RM125 r⁻m⁻, arg, leu (pKSR101) deposited in the FRI as FERM BP-504.

Inventors: BEPPU, TERUHIKO, SEKINE, SUSUMU, TSUCHIYA, MAKOTO, UOZUMI, TAKESHI
Applicants: BEPPU, TERUHIKO
Application year: 1985
Main classification: C12N15
IPC codes: C12N9, C12R1, C12P21, C12N15, C12N1